We are inspiring human belief in a healthier world
Our founding mission is to make highly quality medicines affordable and accessible to the world
30 years of Service in the pharmaceutical industry, backed by proven track record in R&D excellence
Our mission to enable access to affordable medicines and improve lives flow from the top
Expanding our presence to serve more people and create meaningful impact
Being acknowledged for our efforts motivates our entire team
Our expertise across APIs, global generics, biosimilars and custom pharmaceutical services is secured by a strong R&D backbone
We have steadily invested in a wide range of innovations to make our product portfolio diverse and differentiated in a competitive market
The path to serving patients better
World-class and differentiated portfolio in chronic therapy areas
Achieving a sustainable health equity
Fully integrated services across the value chain
Committed to transforming standards of care
Researching areas of unmet medical need
Our expertise rest on the pillars of our advanced R&D capabilities, world-class manufacturing facilities, our long legacy of trust and our partnerships
Research excellence for us means to invest in the future of health for the world
We invest in cutting edge research to develop new cures for challenging diseases
Built to world-class standards, our facilities enable us to produce high-quality and affordable medicines
Legacy of trust
Growing better, together
We are committed to making a positive impact by contributing to healthy communities and leading a responsible business
Aiming for a sustainable environment
A constant focus on sustainable environment with focus on health and safety
A steadfast commitment to enable communities
Hetero aims to report comprehensively and transparently for all stakeholders
Find range of resources including press releases, featured stories and information on social media channels
Access our latest press releases and resources for News and Media section
Discover the stories that enumerate the way we understand disease and develop medicines
Latest media releases and statements in the Hetero newsroom
Browse and download multimedia resources for use
Notices
Back
Hyderabad, India and Budapest, Hungary; 10 June 2026 – Gedeon Richter Plc. (“Richter”) and Hetero Labs Ltd. (“Hetero”) today announce the signing of a global collaboration agreement for the joint development, registration, and commercialization of Semaglutide Injection (generic of Ozempic®), strengthening their long-term partnership and expanding access to affordable treatments for patients worldwide.
The agreement combines the companies’ complementary strengths under a coordinated global framework, with clearly defined territorial responsibilities and a balanced cost- and profit-sharing model. Operating through a joint governance structure, the partners ensure aligned decision-making and efficient execution.
Hetero has already made significant development investments, including technology setup and registration batch manufacturing. Regulatory filings are underway, with EU and US submissions planned for 2027. The collaboration leverages Hetero’s proven market reach within the United States and Emerging Markets, as well as Richter’s well-established commercial infrastructure across Europe and Central Asia, while maintaining optionality for future European manufacturing by Richter.
Dr. Bence Kovács, Global Head of General Medicines at Richter, said: “This collaboration reflects the strong alignment, commitment, and shared pursuit of excellence between Hetero and Richter, forming a powerful partnership. It will enable us to deliver high‑quality, affordable therapies to patients living with diabetes and related cardiometabolic conditions worldwide.”
Dr. Vamsi Krishna Bandi, Managing Director, Hetero Labs Ltd., said: “We are delighted to collaborate with Richter, as our strategic partner for Semaglutide Injection. This strategic Partnership brings together the deep local expertise of Hetero and Richter to broaden the global access to Semaglutide Injection therapy.”
About Richter
Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.8bn and sales of EUR 2.3bn in 2025, it operates Central Europe’s largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women’s Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com
About Hetero
Hetero is a leading global pharmaceutical company focussed on development, manufacturing and commercialization of Active Pharmaceutical Ingredients (APIs) and generic formulations. The company is dedicated to improving patient outcomes by transforming science and technology into high-quality, affordable therapies. A trusted partner to multinational pharmaceutical companies and global procurement agencies, Hetero is headquartered in Hyderabad, India, and has a presence in over 145 countries. With more than three decades of experience, Hetero is supported by a workforce of over 30,000 professionals committed to expanding access to essential medicines worldwide. www.hetero.com
Ozempic®, is a registered trademark of Novo Nordisk A/S.
For further information:
Richter
Hetero